Purpose
This page makes the trade-offs visible when a treatment looks promising, expensive, toxic, uncertain, burdensome, or poorly matched to a patient goal.
Educational use only
The score is a simplified teaching exercise. It supports structured reflection on trial evidence, absolute benefit, toxicity, patient burden, and resource consequences. It does not replace national reimbursement assessment, cost-effectiveness modelling, trial interpretation, patient preference, clinical judgment, or MDT decision-making.
The optional QALY and ICER fields are recorded as context only. They are not included in the score.
Why this fills a gap
Formal value frameworks and health technology assessments exist, but bedside and MDT discussions often need a simpler transparent structure.
Traditional trial reading often separates relative effect, absolute benefit, toxicity, quality of life, cost, and uncertainty into different parts of a paper or reimbursement report. This tool puts those domains on one page so the assumptions can be challenged.
It should not be presented as a validated value framework. Its function is to make the reasoning explicit before a formal guideline, reimbursement, or clinical decision is made.
Compass method
The total score is scaled to 100 points. Higher scores mean a stronger discussion signal, not a treatment recommendation.
Formula
clinical_benefit_score + safety_tolerability_score + evidence_confidence_score + patient_implementation_fit_score + resource_reasonableness_score
Maximum score = 100. QALY gain, ICER, and local reimbursement notes are contextual fields only.
Domain weights
- Clinical benefit: 35 points
- Safety and tolerability: 20 points
- Evidence confidence: 20 points
- Patient and implementation fit: 15 points
- Resource reasonableness: 10 points
| Domain | What it asks | Why it matters |
|---|---|---|
| Clinical benefit | How large is the absolute and relative benefit? | Prevents overreading a small absolute gain with an impressive hazard ratio. |
| Safety and tolerability | How frequent, severe, chronic, reversible, or fatal are the harms? | Separates manageable toxicity from irreversible or hospitalising toxicity. |
| Evidence confidence | How mature, relevant, and externally valid is the evidence? | Weak comparators, immature data, crossover, or exploratory subgroups reduce confidence. |
| Patient and implementation fit | Does the treatment match the patient goal and practical situation? | A population benefit may not fit frailty, travel burden, symptoms, or care goals. |
| Resource reasonableness | Is the cost and delivery burden proportionate to the likely benefit? | Cost should be explicit, but not reduced to a QALY counter in this educational tool. |
Score exercise
Enter simplified trial or treatment data. Blank numeric fields are treated as unavailable and will reduce certainty or trigger caution flags.
Interpretation bands
- 0 to 34: weak or highly uncertain value signal.
- 35 to 54: mixed value signal. Benefits, harms, cost, or uncertainty need close review.
- 55 to 74: favourable discussion signal if patient fit and evidence validity are acceptable.
- 75 to 100: strong discussion signal. Still not an automatic treatment recommendation.
Example loaders
Synthetic examples for teaching the logic.
NTOG treatment value discussion score
The score is only a structured discussion aid. It is not a recommendation, formal health-economic assessment, or QALY calculator.
Structured export
Example matrix
The examples are illustrative. They are not treatment recommendations.
| Scenario | Benefit pattern | Harm pattern | Evidence pattern | Cost pattern | Typical discussion signal |
|---|---|---|---|---|---|
| Clear benefit | OS gain, favourable HR, good absolute effect | Manageable and reversible toxicity | Phase III, mature, active comparator | Moderate cost or favourable access | Favourable to strong |
| Relative-only signal | Impressive HR but small absolute gain | Moderate toxicity | May be statistically strong but clinically narrow | Variable | Mixed, requires absolute-benefit discussion |
| Costly uncertain option | Small or surrogate benefit | Meaningful toxicity or burden | Immature or indirect evidence | High cost and high resource pressure | Weak to mixed |
Relationship to existing frameworks
This NTOG page is intentionally simpler than formal value frameworks and HTA methods.
- ASCO Value Framework: clinical benefit, side effects, symptoms or quality of life, and cost context. ASCO value in cancer care
- ESMO-MCBS: graded magnitude of clinical benefit for cancer medicines. ESMO-MCBS
- NICE health technology evaluation: economic evaluation, resource use, costs, uncertainty, subgroup analysis, and benefits not captured in QALY calculations. NICE economic evaluation manual
Limitations
A number can hide more than it reveals unless the assumptions are made explicit.
- Median OS benefit may not reflect long-term survivors, delayed separation of curves, or cure fraction.
- Hazard ratios do not show absolute benefit and may mislead when hazards are non-proportional.
- NNT and NNH depend on time point, baseline risk, endpoint choice, censoring, and follow-up duration.
- QoL data can be missing, selectively reported, or collected after dropout from treatment.
- Cost thresholds differ between countries, payers, reimbursement systems, and negotiated prices.
- Subgroup results may be underpowered, exploratory, or biologically plausible but not proven.
- Patient goals, frailty, symptoms, travel burden, and family context may override a population-level value signal.